US/UK/Canada

Share

About Us

Karo Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment.

Contacts

  • Karo Pharma
    Nybrokajen 7, 111 48 Stockholm Sweden
    +46 8 608 60 00
    http://www.karopharma.se
  • Carl Lindgren

    Vice President


    +46 76 002 60 22
    • Pick a time period -
    Tags ( Active)

    Karo Healthcare appoints Egil Molsted Madsen as CFO

    We are pleased to announce that Egil Molsted Madsen will assume the role of CFO at Karo starting on 3 October 2024.   Egil, a Danish national, brings a wealth of experience from his previous roles as CFO in the healthcare sector at companies such as Atos Medical, ISS Diagnostica and Agilent/Dako, as well as valuable experience in operating within a private equity context.  Egil has over 15 years of experience as a CFO and qualified as a state authorised public accountant before moving into operational finance roles.   “It is with immense pleasure that I welcome Egil to Karo.

    Karo Group publishes the 2023 Sustainability Report

    Today, on 15 April 2024, Karo Group* is publishing its 2023 Sustainability Report on the company’s website, www.karohealthcare.com.   For further information, please contact: Christoffer Lorenzen, CEO, +46 735 017 620, christoffer.lorenzen@karo.com  Lisa Westerdahl, Chief People & Sustainability Officer, +46 733 297 004, lisa.westerdahl@karo.com   About Karo Group Karo Group consists of Karo Intressenter Holding AB and its subsidiaries including Karo Healthcare. Karo is a leading European consumer healthcare company with the purpose of delivering "Smart choices for

    Karo Healthcare expands its presence in Italy with the acquisition of the rights to Proctosedyl® from Bayer

    Karo Healthcare AB (‘Karo’) announces the acquisition of the rights to the OTC brand Proctosedyl from Bayer.   The transaction transfers global dossier ownership to the OTC pharmaceutical Proctosedyl, and exclusive license to the Proctosedyl trademark in Italy, from Bayer to Karo. This acquisition amplifies Karo’s presence in Italy while aligning with Karo’s M&A strategy of focusing on brands with strong equity in categories associated with discomfort and embarrassment.      Proctosedyl is a leading brand in Italy for the treatment of hemorrhoids. The acquisition strengthens and

    Karo Healthcare completes the acquisition of the rights to the Global OTC brand Lamisil® from Haleon

    Karo Healthcare (‘Karo’) has today completed the previously announced acquisition of the rights to the Global OTC brand Lamisil® from Haleon UK Holdings Ltd. (‘Haleon’) for a total consideration of GBP 235m (EUR 274m). All the necessary conditions for the completion of this transaction have been fully met.   Lamisil is a leading brand for the treatment of fungal infections like Athlete’s foot[1], and with a net sales of EUR 65m in 2022 the brand significantly strengthens our position in the Foot Health category.   “We are proud to welcome Lamisil to our Karo family and look

    Karo Healthcare acquires the Global OTC brand Lamisil® from Haleon

    Karo Healthcare (‘Karo’) announces the acquisition of the rights to the Global OTC brand Lamisil® from Haleon UK Holdings Ltd. (‘Haleon’) for a total consideration of GBP 235m (EUR 274m) (‘Transaction’). The Transaction transfers ownership of Haleon's topical Lamisil business, which had net sales of EUR 65m in 2022, to Karo. The acquisition scales up Karo’s operations in major European markets as well as expands its presence in markets beyond the current geographical reach. Lamisil is a leading brand for the treatment of fungal infections like Athlete’s foot and is trusted by

    Babak Peyami Joins Karo’s Corporate Management Team as new Head of Digital Commerce

    Karo Healthcare announces changes to its Corporate Management Team. Robin List transitions to an advisory role and Babak Peyami is promoted to drive Karo’s digital commerce activities.   Babak joined Karo in 2021 as part of the Sylphar acquisition and brings extensive digital expertise to our organization. Alongside Arash Peyami, Babak co-founded Nutravita, a digital-first brand that has become Karo's second-largest brand under their joint leadership. Arash will continue to play a vital role in driving the digital business together with Babak, ensuring the establishment of an optimal

    Karo Healthcare publishes the 2022 Sustainability Report

    Today, on 24 April 2023, Karo Healthcare is publishing its first separate Sustainability Report on the company’s website, www.karohealthcare.com.   For further information, please contact: Christoffer Lorenzen, CEO, +46 735 017 620, christoffer.lorenzen@karo.com Lisa Westerdahl, VP of People, Sustainability and Corporate Communication, +46 733 297 004, lisa.westerdahl@karo.com   The report is published in English only. This information was submitted for publication on 24 April 2023, at 15:00 CET.     About Karo Healthcare Karo Healthcare is a leading European

    Michael Kaltenborn appointed CSDO at Karo

    Karo Healthcare (“Karo”) has appointed Michael Kaltenborn as Chief Strategy & Corporate Development Officer (CSDO). The appointment of Michael Kaltenborn reflects Karo’s ambition to grow via M&A and to continue to acquire attractive consumer healthcare brands and portfolios. The appointment strengthens the international profile of Karo’s organization and leadership team.   “We are excited to welcome Michael to Karo, and I am pleased that we have been able to attract such a strong profile to Karo. Michael brings a unique and strong M&A track record and has been involved in more than

    Karo Pharma Aktiebolag’s application for de-listing has been approved

    Karo Pharma Aktiebolag’s (“Karo Pharma” or the “Company”) application for de-listing has now been approved by Nasdaq. The last day of trading in Karo Pharma’s share on Nasdaq First North Growth Market will be 24 November 2022.As previously announced, Karo Pharma has applied for de-listing of the Company’s shares from Nasdaq First North Growth Market. Nasdaq has now approved the application and resolved that the last day of trading will be 24 November 2022. For further information, please contact: Christoffer Lorenzen, CEO, +46 73-501 76 20, christoffer.lorenzen@karopharma.com Jon

    Karo Pharma Aktiebolag applies for de-listing

    The Board of Directors of Karo Pharma Aktiebolag (“Karo Pharma” or the “Company”) has resolved to apply for de-listing of the Company’s shares from Nasdaq First North Growth Market following that Karo Intressenter AB[1] (“Karo Intressenter”) controls more than 90 percent of the shares in Karo Pharma and has initiated compulsory redemption of the remaining shares in the Company On 16 August 2022, Karo Intressenter announced a public cash offer to the shareholders in Karo Pharma to acquire the shares in Karo Pharma not already held by Karo Intressenter at a price of SEK 60 per share (the “

    Karo Intressenter AB initiates compulsory redemption

    On 16 August 2022, Karo Intressenter AB[1] (“Karo Intressenter”) announced a public cash offer to the shareholders in Karo Pharma Aktiebolag (“Karo Pharma” or the “Company”) to acquire the shares in Karo Pharma not already held by Karo Intressenter at a price of SEK 60 per share (the “Offer”). On 19 September 2022, Karo Intressenter announced the outcome of the Offer, that they completed the Offer and that Karo Intressenter thereby, at the time of the publication of the announcement, controlled in total approximately 93.7 percent of the total number of shares and votes in Karo Pharma. At

    Karo Pharma Aktiebolag comments on the public offer from Karo Intressenter AB and obtains a fairness opinion

    Background On 16 August 2022, Karo Intressenter AB[1] ("Karo Intressenter") announced a public cash offer to the shareholders in Karo Pharma Aktiebolag ("Karo Pharma") to acquire the shares in Karo Pharma not already held by Karo Intressenter (the "Offer") at a price of SEK 60 per share (the "Consideration"). As of the date of this press release, Karo Intressenter holds 236,720,058 shares in Karo Pharma, corresponding to 86.6 per cent of the share capital and votes in Karo Pharma. Hence, Karo Intressenter is the parent company of Karo Pharma. The acceptance period for the Offer

    Comment from Karo Pharma Aktiebolag's board of directors regarding the public offer from Karo Intressenter AB

    Today, on 16 August 2022, Karo Intressenter AB[1] ("Karo Intressenter") announced a public cash offer to the shareholders in Karo Pharma Aktiebolag ("Karo Pharma") to acquire the shares in Karo Pharma not already held by Karo Intressenter at a price of SEK 60 per share (the "Offer"). For further information about the Offer, please refer to Karo Intressenter's press release . Karo Intressenter is expected to publish an offer document

    Interim report H1 2022

    January – June · Revenues amounted to MSEK 1 965.3 (1 460.9), corresponding to an increase of +35% for the period.  · The organic growth1 during the period was +6%. The currency impact was +3% while the acquisitions of the Sylphar Group and E45[®] brand portfolio from Reckitt generated growth of +26%. · EBIT (Operating Profit) amounted to MSEK 3.8 (159.1), corresponding to a decline of 98%. · EBITDA[1] amounted to MSEK 394.6 (440.4) corresponding to a decline of 10%. Adjusted for non-recurring transactional cost of 92.0 MSEK directly related to the acquisitions of new

    Karo Pharma’s rights issue fully subscribed

    Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction in which the distribution or release would be unlawful or require further registration measures. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “Important information” below.The result of Karo Pharma Aktiebolag’s (“Karo Pharma”) rights issue of approximately SEK 2.5 billion (the “Rights Issue”) shows that 47,954,417

    Karo Pharma publishes the 2021 annual report

    Today, on 12 April 2022, Karo Pharma is publishing its annual report for 2021 on the company’s website, www.karopharma.com.     For further information, please contact:Lisa Westerdahl, Head of Corporate Communication, 073-329 70 04, lisa.westerdahl@karopharma.comJon Johnsson, CFO, 073-507 88 61, jon.johnsson@karopharma.com     The Annual Report is published in Swedish and English. The Swedish version represents the original version and has been translated into English.   This information is information that Karo Pharma is obliged to make public pursuant to the

    Karo Pharma completes the acquisition of the E45® brand from Reckitt

    Karo Pharma Aktiebolag (“Karo”) has today completed the previously announced acquisition of the skin health brand, E45®, from Reckitt for a total consideration of GBP 200m. All conditions to the completion of the transaction have been satisfied.Net sales of E45® was GBP 43m in 2021 and the transaction contributes positively to Karo’s market position within skin health, particularly in the UK, South Africa and Spain. “E45 is a unique brand, which is trusted by consumers and represents quality and consistency, and we see compelling opportunities to unlock value and develop the brand via

    Karo Pharma publishes prospectus relating to the rights issue and receives approval to change listing venue to Nasdaq First North Growth Market

    Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction in which the distribution or release would be unlawful or require further registration measures. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “Important information” below.The prospectus relating to the rights issue in Karo Pharma Aktiebolag (“Karo Pharma”) of approximately SEK 2.5 billion (the “Rights Issue”) has

    Karo Pharma resolves on a fully guaranteed rights issue of approximately SEK 2.5 billion and announces the terms of the rights issue

    Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction in which the distribution or release would be unlawful or require further registration measures. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “Important information” below.Karo Pharma Aktiebolag (”Karo Pharma”) has, by power of authorisation from the annual general meeting on 21 April 2021, resolved to carry out a new

    Karo Pharma receives approval to delist the Company’s share from Nasdaq Stockholm in connection with the change of listing venue to Nasdaq First North Growth Market

    Karo Pharma Aktiebolag (publ) (the “Company” or ”Karo Pharma”) announced in a press release on 9 March 2022 that Karo Pharma’s Board of Directors has decided to apply for delisting of the Company’s share from Nasdaq Stockholm as well as listing on Nasdaq Stockholm First North Growth Market, and that the application on delisting had been submitted to Nasdaq Stockholm. Today, the Company has received approval of delisting of the Company’s share from Nasdaq Stockholm. Nasdaq Stockholm’s approval is conditional on Karo Pharma’s share being approved for admission to trading on Nasdaq First North

    Karo Pharma applies for delisting of the Company’s shares from Nasdaq Stockholm, in connection with the change of listing venue to Nasdaq First North Growth Market

    The Board of Directors of Karo Pharma Aktiebolag (publ) (the “Company” or “Karo Pharma”) has today decided to apply for and submitted the application regarding delisting of the Company’s shares from Nasdaq Stockholm as well as decided to apply for listing of the Company’s shares on Nasdaq First North Growth Market (the “First North-listing”).As communicated on 15 December 2021, the Board considers that Nasdaq First North Growth Market, with its more suitable regulatory environment and lower cost of complying with continuing obligations, is a more appropriate listing venue for the Company

    Year-end report 2021

    Q4, October – December · Revenues amounted to MSEK 762.0 (721.2), corresponding to an increase of +6% for the period. · The organic growth[1] during the fourth quarter was +9%. The currency impact in the quarter was 1% while the acquisitions adjusted for the divestments generated a net effect of -5%. · EBIT (Operating Profit) amounted to MSEK -52.7 (-16.1), corresponding to a decrease of 228%. · EBITDA[1] (Operating Profit after depreciation and amortization) amounted to MSEK 96.9 (114.7) corresponding to a decrease of 16%. · The gross margin[1], defined as gross profit

    Karo Pharma completes the acquisition of Sylphar International NV

    Karo Pharma Aktiebolag (“Karo”) today announces that the previously announced acquisition of the Belgian fast-growing digital-first brand company Sylphar International NV (“Sylphar”) for EUR 290m has been successfully completed according to plan. The transaction is expected to contribute positively to Karo’s market position and further enhance Karo’s strong platform for continued growth, particularly in the digital marketplace. Effective today, Robin List, CEO of Sylphar, shall join the Karo Corporate Management Team, reporting to Christoffer Lorenzen, CEO. Robin shall continue to

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe